Bracing for Meridia

With fen-phen out and Meridia (sibutramine hydrochloride monohydrate) now dominating the prescription weight-loss market, Knoll Pharmaceuticals began shipping the neurotransmitter reuptake inhibitor full-force this spring. The company also is launching a free behavioral and dietary support program that patients can enroll in through participating pharmacists.

The drug will be available in 5, 10, and 15 mg doses, although one 10 mg capsule a day is recommended as the starting dose. Meridia is specifically indicated on the Body Mass Index scale for patients over 30 kg/m2, or over 27 kg/m2 if risk factors such as hypertension or diabetes are known.

[Editor's note: To receive a comprehensive report describing Knoll Pharmaceuticals' clinical trials and patient support offerings, call the company (800) 526-0221.]